Monthly Archives: July 2012

OVA-1 Testing in Ovarian Cancer – pro

OVA1 test is FDA cleared for women who meet the following criteria: (i) over age 18, (ii) ovarian adnexal mass present for which surgery is planned, and (iii) not yet referred to an oncologist. It is an aid to further assess the likelihood that malignancy is present when the physician’s independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation

Read more
What is Cancer?

This is a 3D medical animation that helps to explain the answer to the question "what is cancer?" Thank you to biodigitalsystems for allowing us to share this video.

Read more
Killer T Cell Attacking Cancer

In this video, you will see how a Killer T Cell attacks Cancer. This video is courtesy of Cambridge University.

Read more
Proton Beam Radiotherapy

Charged-particle beams consisting of protons or helium ions are a type of radiation therapy that uses particles which is different from conventional radiation that uses electromagnetic (i.e., photon) radiation. Particles have the unique properties of minimal scatter as the particulate beams pass through the tissue. As such, there is less “collateral damage” to the surrounding tissue and it is possible to ensure a more precise deposition of the

Read more
Chemo Options for Later Lines of Therapy for Metastatic Colon Cancer

There are now five different classes of drugs with significant antitumor activity in colon cancer: Fluoropyrimidine(5-fluorouracil [5-FU] which is usually given with leucovorin [LV], capecitabine, tegafur plus uracil [UFT]), Irinotecan, Oxaliplatin, Cetuximab and panitumumab (Vectbix). The latter two are monoclonal antibodies (MoAbs) directed against the epidermal growth factor receptor (EGFR), and bevacizumab, is a monoclonal antibody targeting

Read more
Herceptin and Arimidex for HER+, ER/PR+ Metastatic Breast Cancer

Is there a way to make cancers that stop responding to hormones increase their sensitivity to these drugs? Preclinical evidence suggests Herceptin (trustusumab) can restore and amplify responsiveness to hormonal therapy. The combination of Tykerb, which like Herceptin works on the HER receptor, and Femara is FDA approved and is thought to work through this mechanism. A randomized phase III TAnDEM study investigated Trastuzumab plus Arimidex(anastrozole)

Read more
Tarceva for Maintenance in Non-small Cell Lung Cancer

Tarceva (erlotinib) is FDA approved for non-small cell lung cancer after standard chemo has failed. Older studies showed that it does not contribute to chemotherapy in first-line. It is being studied for first line therapy of lung cancer instead of chemotherapy. This drug has been studied primarily in stage IV, when it has spread but recently it has been also studied, for maintenance, once treatment with chemotherapy had stopped. Maintenance means

Read more
MRI in the Diagnosis and Followup of Multiple Sclerosis

Magnetic Resonance Imaging (MRI) of the brain is useful in the diagnosis and treatment of multiple sclerosis (MS), because it is an inflammatory, demyelinating condition of the central nervous system (CNS) that MRI can visualize. Therefore, the activity of the disease can be quantified and tracked over time, with treatment. White matter tracts are affected, including those of the upper brain, lower brain, and spinal cord. MS lesions, known as plaques,

Read more
Repeat Allogeneic Stem Cell Transplantation for ALL

ALL is the most common cancer diagnosed in children and young adults, represents almost 25% of cancers in children younger than 15 years. Complete remission of disease is now typically achieved with pediatric chemotherapy regimens in approximately 95% of children with ALL, with up to 85% long-term survival rates. Young adults are treated as children, but the relapse rate is higher.  Allogeneic stem cell transplantation is an important salvage option

Read more
Antiviral Prophylaxis after Transplantation

The post transplant period is dangerous because of immunosuppression and there is high risk of various infections after transplantation. The most dangerous and difficult to treat are viral infections. Post transplantation prophylaxis, however, is not a simple matter because of the potential toxicity of treatments in very ill patients. Ribavirin alone is not currently considered appropriate for post-transplant prophylaxis without evidence of infection.

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/archive.php on line 56